Executive Leadership Team

Ian C. Read
Chairman of the Board and Chief Executive Officer

Ian C. Read leads Pfizer, one of the world’s premier innovative biopharmaceutical companies, which brings therapies to patients that significantly improve their lives. These include medicines, vaccines and many of the world’s best-known consumer health care products.

Prior to being named Chairman of the Board in 2011, and Chief Executive Officer in December 2010, he served as Senior Vice President and Group President of the Worldwide Biopharmaceutical Businesses, which he led from 2006 through December 2010. In that role, he oversaw five global business units—Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets. Mr. Read began his career with Pfizer in 1978 as an operational auditor. He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in 2002. Mr. Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.

Ian is a Director of Kimberly-Clark Corporation. He also serves on the Boards of Pharmaceutical Research and Manufacturers of America (PhRMA), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and the Partnership of New York City.

Ian received his B.Sc. in chemical engineering from London University Imperial College in 1974 and earned his Chartered Accountants certification from the Institute of Chartered Accountants of England and Wales.

Albert Bourla, DVM, Ph.D.
Group President, Pfizer Innovative Health

Albert Bourla is the group president of Pfizer Innovative Health at Pfizer Inc., one of the world’s premier innovative biopharmaceutical companies.

Pfizer Innovative Health includes six business groups: Consumer Healthcare, Inflammation & Immunology, Internal Medicine (neuroscience and pain, and cardiovascular and metabolic), Oncology, Rare Disease and Vaccines. Each business group is committed to improving health with our innovative products from prevention to treatment to wellness – at every stage of life in communities across the globe. It also includes the Patient and Health Impact group, which is focused on developing solutions for increased patient access, demonstrating the value of our innovations, and ensuring broader business model innovation.

Albert has almost 25 years of experience with Pfizer and has held a number of senior global positions across a range of markets and disciplines. Before assuming his current role, Albert was the group president of Pfizer’s Global Vaccines, Oncology and Consumer Healthcare Business. Previously, he was president and general manager of Pfizer’s Established Products Business, where he led the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio (including legacy brands and generics).

Albert joined Pfizer’s Animal Health Division in 1993 as technical director of Greece. He held positions of increasing responsibility across Europe before moving to Pfizer Global Headquarters in New York in 2001 to assume the role of U.S. group marketing director for Animal Health. In 2004, he became vice president of Business Development and New Products Marketing; supervising Pfizer Animal Health global licensing and acquisition activities, as well as the unit’s R&D portfolio. In 2006, he was appointed area president of Europe, Africa and Middle East and in 2009, he assumed additional responsibilities for Asia and Pacific.

Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. Albert is a member of the following boards: the Pfizer Foundation, which promotes access to quality health care and the Biotechnology Innovation Organization (Bio), the world's largest biotechnology trade association.

Frank D'Amelio
Executive Vice President, Business Operations and Chief Financial Officer

Frank D’Amelio is the executive vice president, business operations and chief financial officer of Pfizer, responsible for finance, business development and business operations, including IT, procurement and real estate. Frank led the acquisition and integration of Medivation, Inc., Anacor Pharmaceuticals Inc., Hospira Inc., King Pharmaceuticals Inc. and Wyeth, as well as the split-off of Pfizer’s animal health business, Zoetis, and the sale of its nutrition business to Nestle and its Capsugel business to KKR.

Before joining the company in September 2007, he was senior executive vice president of integration and chief administrative officer of Alcatel-Lucent, responsible for the integration of the Alcatel-Lucent merger as well as procurement, real estate, IT and supply chain.

Prior to the merger of Alcatel and Lucent Technologies in 2006, Frank was the chief operating officer of Lucent Technologies. In 2001, he was appointed executive vice president and chief financial officer of Lucent, where he helped lead the company through one of the most challenging periods in the telecom industry’s history and returned the company to profitability.

When Lucent was spun off from AT&T in 1996, Frank helped create the new company financially as the chief financial officer of Lucent’s Network Systems Business and was a critical member of the team that met with investors around the world during Lucent’s initial public offering. In 1999, he was appointed the Group President of Lucent’s Switching Solutions Business Unit, where he led Lucent’s multibillion-dollar, global Switching, Access and Application Software businesses.

Born and raised in New Jersey, Frank earned his M.B.A. in Finance from St. John’s University and his B.A. in Accounting from St. Peter’s College. He started his career in 1979 at Bell Labs, holding a variety of financial, accounting and general management positions, and moved within AT&T, holding a series of positions with increasing responsibility.

In 2005, 2006, 2011, 2012, 2013, 2014 and 2016, Frank was ranked among America’s top CFOs by Institutional Investor magazine. In 2002, he was recognized by Treasury & Risk Magazine as one of America’s Top CFOs.

He currently serves on the Board of Directors of Zoetis, Inc. and Humana, Inc. and is chair of the Humana Audit Committee; and the Independent College Fund of New Jersey.

Mikael Dolsten, M.D., Ph.D.
President, Worldwide Research and Development

Mikael Dolsten is focused on advancing the company’s scientific leadership in small molecule medicines, biotherapeutics and vaccines. He is a member of the company’s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities. He leads the Worldwide Research and Development (WRD) organization at Pfizer, which is responsible for research at the company, including development of all compounds through proof of concept, and provides safety, regulatory and clinical operation support to the entire R&D pipeline.

The WRD group contains all Pfizer research units, including Oncology, Inflammation & Immunology, Vaccines, Cardiovascular & Metabolic Disease, Neuroscience, Rare Disease, as well as the Centers for Therapeutic Innovation (CTI) and the biotech unit, Rinat. Mikael also has worldwide responsibility for Pfizer’s groups in safety, regulatory and external R&D innovation, in addition to science-based teams in pharmaceutical sciences, drug safety R&D, and large and small molecule discovery and development.

Prior to joining Pfizer in 2009, Mikael was President of Wyeth Research, where he led scientists across the U.S., Europe and Asia.

Mikael earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden, where he was appointed Adjunct Professor in Tumor Immunology. He is a fellow of the New York Academy of Medicine. Mikael serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors. He is a member of the Board of Karyopharm Therapeutics Inc. and an industry member of the Government-University-Industry Research Roundtable (GUIRR) Council. In addition, Mikael serves as the chairman of the Translational Advisory Board of the venture capital firm, AppleTree Partners.

Mikael is a named inventor on several patents and has published approximately 150 articles in international journals, with particular contributions in areas such as molecular cell biology, immunology and oncology.

Chuck Hill
Executive Vice President, Worldwide Human Resources

As chief human resources officer, Chuck Hill is responsible for all enterprise human resource strategies with a key focus on driving the company’s OWNIT! culture.

Chuck joined Pfizer’s human resources team in 1987, supporting the Pharmaceutical Sales Force. Since then, he has held a number of roles including HR director of Pfizer’s Global Manufacturing facility in Groton, Connecticut; vice president HR, corporate finance; and senior vice president HR, Worldwide Biopharmaceuticals Businesses.

Prior to joining Pfizer, Chuck served for eight years in the United States Air Force as an instructor fighter pilot and flight commander. Chuck is the executive sponsor of the Pfizer Colleague Council, Veterans in Pfizer, which works to maximize the unique role veterans and active military personnel play in driving workplace and marketplace outcomes.

Chuck holds a B.A. in business from Rutgers University and an M.S. in Systems Management from the University of Southern California. Chuck and his wife, Cathy, have two children and live in Connecticut.

Rady Johnson
Executive Vice President, Chief Compliance and Risk Officer

Rady Johnson has overall responsibility for Pfizer’s corporate compliance programs and reports to the chief executive officer. Rady has been with Pfizer since 1994 and has served in a number of leadership positions, including as associate general counsel for the Specialty Care Business Unit and as head of the global product and regulatory law practice group.

Prior to joining the company, Rady was a member of Hogan & Hartson, LLP’s food and drug law practice group based in Washington D.C., and also worked as a certified public accountant (CPA) and senior auditor for Arthur Anderson & Co.

Rady graduated from the University of Richmond and Georgetown University Law Center.

Doug Lankler
Executive Vice President and General Counsel

Doug Lankler joined Pfizer in 1999 and currently serves as general counsel. Prior to being named general counsel, Doug was Pfizer's chief compliance and risk officer, a role he assumed in 2006.

Prior to joining the company, Doug was with the United States Department of Justice as an Assistant U.S. Attorney in the Southern District of New York. Doug was a recipient of the United States Attorney General's Distinguished Service Award.

Doug graduated from the State University of New York at Albany and Cornell Law School. He and his wife, Jill, have three children and reside in Larchmont, N.Y.

Freda C. Lewis-Hall, M.D., DFAPA
Executive Vice President and Chief Medical Officer

Freda Lewis-Hall serves as Pfizer’s chief medical officer and leads Pfizer Medical, the division responsible for the safe, effective and appropriate use of Pfizer medicines and vaccines around the world. Besides providing science-grounded medical information to prescribers and patients, Pfizer Medical is also responsible for the company’s office of patient affairs, its centers of excellence on pediatric care, clinical trial diversity and healthy aging, its enterprise benefit-risk communications, and its worldwide compassionate access program.

Before joining Pfizer in 2009, Freda held senior leadership positions in medical affairs and product development with Vertex, Bristol-Myers Squibb, Pharmacia and Eli Lilly and Company. Prior to joining the biopharmaceutical industry, she served as vice chairperson and associate professor in the Department of Psychiatry at Howard University College of Medicine and was an advisor to the National Institute of Mental Health. She graduated from Johns Hopkins and earned her medical doctorate at Howard University College of Medicine. She launched her medical career as a practicing physician and then focused her academic research on the effects of health care disparities and the impact of mental illness on families and communities.

Freda is a Distinguished Fellow of the American Psychiatric Association. She is a frequent speaker on issues such as improving patient safety and outcomes and reducing stigma and healthcare disparities. She appears regularly on health-related television programs in major global markets, including CBS-syndicated shows such as The Doctors and Dr. Phil. She also shares health and medical information through GetHealthyStayHealthy.com.

Freda was the inaugural Chair of the NIH’s Cures Acceleration Network Review Board. She currently serves on the boards of Tenet Healthcare Corporation, Save the Children, Harvard Medical School and the Patient Centered Outcomes Research Institute. She is a director of the Foundation for the National Institutes of Health (NIH) and a member of the Advisory Council for the NIH’s National Center for Advancing Translational Science.

Kirsten Lund-Jurgensen, Ph.D.
Executive Vice President and President, Pfizer Global Supply

Kirsten was named executive vice president and president, Pfizer Global Supply (PGS) in December 2016 and is responsible for Pfizer’s internal and external supply network.

Kirsten's pharmaceutical industry career spans 30 years, the last 17 with Pfizer, after joining the company from SmithKline Beecham in 1999 as vice president, global supply chain management, Pharmaceuticals. At SmithKline Beecham (Germany, Australia and the U.S.), Kirsten held several operational and functional roles, including site leader of consumer and pharmaceutical plants; vice president, global strategic planning; and vice president, contractor management, Europe. Kirsten was named vice president, supply chain management for all Pfizer global businesses in 2000. She then led the Patented Products Operating Unit (Manufacturing Sites in Europe and Singapore) 2008-2009, and the Primary Care and Oncology, Operating Unit (Manufacturing Sites in Europe, Singapore, Canada) 2009-2012. Kirsten was named vice president, Product Portfolio Management for Primary Care, Established Products and Oncology in 2012. Kirsten was appointed as product portfolio management lead and PGS lead for Vaccines, Oncology, and Consumer in 2014 and subsequently vice president, Innovative Health Product Portfolio Management and Consumer Operations.

Kirsten has been a member of the PGS Leadership Team since 2000, and was the PGS lead on several of Pfizer’s Business Leadership Teams (Pfizer Consumer, Primary Care, Specialty Care, Established Products and Pfizer Innovative Health) driving collaboration between global supply and commercial teams.

Kirsten was elected to the Pfizer Foundation Board in 2008. She chaired Pfizer’s Environmental Sustainability Council from 2009 through 2016 and was named Executive Leadership Team (ELT) sponsor for Pfizer’s Environmental Sustainability program in 2017.

Kirsten is a pharmacist from Kiel University in Germany and holds a Ph.D. in Pharmaceutical Biology from Freiburg University in Germany.

Rod MacKenzie, Ph.D.
Executive Vice President, Chief Development Officer

Rod MacKenzie is responsible for the development and advancement of Pfizer’s pipeline of medicines in several therapeutic areas, including metabolic disease and cardiovascular risks, inflammation and immunology, neuroscience, oncology and rare disease. He serves on the Portfolio Strategy and Investment Committee, which focuses on maximizing the return on R&D investment across the Pfizer portfolio.

Rod joined Pfizer in Sandwich, U.K. as a research scientist and conducted medicinal chemistry research in the cardiovascular, gastroenterology, sexual health, urology, allergy and respiratory diseases. Rod is the co-inventor of Enablex™ (darifenacin) and represents Pfizer on the Board of Directors for ViiV Healthcare Limited, a global specialist HIV company established by GlaxoSmithKline and Pfizer to deliver advances in treatment and care for people living with HIV.

Rod graduated from the University of Glasgow with a 1st Class Honors degree in chemistry and completed his Ph.D. at Imperial College, London. He was awarded a NATO Postdoctoral Research Fellowship and spent two years at Columbia University, New York, working in the area of molecular recognition with Professor W.C. Still.

Laurie J. Olson
Executive Vice President, Strategy, Portfolio and Commercial Operations

Laurie Olson is responsible for overseeing the shaping of Pfizer’s longer-term strategy, supporting the execution of Pfizer’s commercial objectives and providing portfolio advisory functions to guide R&D investment decisions. Laurie is a member of the Portfolio Strategy Investment Committee, which oversees decisions regarding enterprise portfolio investment and advancement. Laurie joined Pfizer in 1987 as an analyst in the company’s marketing research organization.

In addition to her daily responsibilities, she is the executive sponsor of Pfizer’s global Lesbian, Gay, Bisexual, and Transgender Colleague Council and serves on the company’s worldwide Diversity Leadership Council.

Laurie earned a B.S. degree in economics from the State University of New York at Stony Brook and an M.B.A. in marketing from Hofstra University.

Sally Susman
Executive Vice President, Corporate Affairs

Sally Susman is executive vice president, Corporate Affairs for Pfizer. She chairs Pfizer’s Political Action Committee and is vice chair of the Pfizer Foundation.

Sally directs Pfizer’s global communications and its public affairs activities, including high-level relations with the governments of all nations in which the Company has operations or markets products. Sally also heads the firm’s corporate responsibility group and plays a key role in shaping the Company’s policy initiatives. Before joining Pfizer in 2007, Sally held roles at Estee Lauder Companies and the American Express Company. Earlier in her career, she spent eight years in government service focused on international trade issues.

Sally serves on the following boards: WPP plc, a world leader in advertising and marketing based in the U.K., and The International Rescue Committee.

John Young
Group President, Pfizer Essential Health

John Young has more than 25 years of experience with Pfizer and has held a number of senior global positions across the organization. A scientist by training, he began his Pfizer career in the U.K. as a trainee sales representative and held various positions in sales and marketing before taking the role of Australia country manager, and, later, U.K. country manager. Following these experiences, he assumed the role of regional president, Europe, Canada, Australia and New Zealand for the Primary Care Business Unit. He was later appointed president and general manager of the Primary Care Business, where he led both the commercial organization and clinical development of medicines in key disease areas including cardiovascular disease, diabetes and pain.

John is a member of the Boards of EFPIA (European Federation of Pharmaceutical Industry Associations), the NCUSCR (National Committee for U.S. China Relations), and has been a member of the U.K. Government bioscience working group, the MISG (Ministerial Industry Strategy Group), since 2008.

John holds a B.Sc. in biological science from Glasgow University and an M.B.A. from Strathclyde Graduate Business School. He is married with three daughters.